BioAge Labs, Inc. Common Stock (BIOA)

• Market cap: $209M
• 1 day: 5.82%
• 5 days: -6.88%
• 1 month: -66.65%
• 3 months: -71.26%
• 6 months: -71.26%
• Year to date: -71.26%
• 1 year: -71.26%
• 5 years: -71.26%
• 10 years: -71.26%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1213.35% more ownership

Funds ownership: 0% [Q2] → 1213.35% (+1213.35%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 20% upside
• Avg. target: $18 209% upside
• High target: $40 587% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

Citigroup Samantha Semenkow 20% 1-year accuracy 3 / 15 met price target	20% upside $7	Neutral Downgraded	9 Dec 2024
Jefferies Roger Song 19% 1-year accuracy 3 / 16 met price target	20% upside $7	Hold Downgraded	9 Dec 2024
Morgan Stanley Jeffrey Hung 35% 1-year accuracy 6 / 17 met price target	587% upside $40	Overweight Initiated	21 Oct 2024